African Access Initiative: “We Will Count Our Success By Seeing Patients Diagnosed Correctly And Treated With The Right Medicine” 05/09/2018 Leila Ueberschlag Some 60 percent more Africans die from cancer than malaria, and the number of cancer deaths is expected to increase almost 70% by 2030, according to experts. Breast, cervical, prostate, lymphoma and colorectal constitute the top five cancers diagnosed on the continent. In order to address this emerging cancer crisis, the African Access Initiative (AAI) was launched over a year ago. Continue reading -> Political Views And Vaccine Refusal Rates An Increasing Concern For Policymakers And Public Health Officials 13/07/2018 Tatum Anderson Or they should be. That’s the conclusion of a recent study published in the medical journal Vaccine. The study focused on political views of parents in the state of California, who had chosen not to vaccinate their nursery-school aged children. And it tracked the number of parents who had filed personal belief exemptions (PBEs), applications for permission to avoid vaccinations over a 5-year period to 2015. A disproportionate number of parents filing such forms were from Republican or conservative neighbourhoods, according to researcher Kevin A Estep, from the health administration and policy program at the university. Continue reading -> Brazil’s Federal Court Reviews Medicines Mailbox Patents 04/05/2018 Guest contributor This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Special Feature: Blocking Taiwan From Joining WHO Affects Global Health Security, Officials Say 09/04/2018 Catherine Saez TAIPEI, Taiwan - Two years after the victory of Taiwan Democratic Progressive Party (DPP) and President Tsai Ing-wen, Taiwan is feeling the effects of the DPP's position against the "One China principle." At the World Health Organization, China is allegedly successfully blocking Taiwan from participating in the annual World Health Assembly, and in a number of WHO technical meetings, officials say. Beyond the political dimension of the dissent between China and Taiwan, the situation may hurt the Taiwanese and global health security, Taiwanese officials said. Continue reading -> Global Health Governance Changing With Shift In Economic Centre Of Gravity, Speakers Say 16/03/2018 Catherine Saez Political and economic shifts have modified the post-war world order, and global health governance has to adapt to this new environment, speakers said at an academic event in Geneva this week. Among the changes: with the decline of United States funding for global health, new actors such as China and India could take leadership roles, they said. Continue reading -> UN Member States Briefed On Innovation And Access To Health Technologies 14/03/2018 William New NEW YORK -- A major event on innovation and access to health technologies took place at the United Nations in New York last week, in which UN member states were briefed on ideas and efforts to promote these issues at the forefront of global health policy. Continue reading -> New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Political Views And Vaccine Refusal Rates An Increasing Concern For Policymakers And Public Health Officials 13/07/2018 Tatum Anderson Or they should be. That’s the conclusion of a recent study published in the medical journal Vaccine. The study focused on political views of parents in the state of California, who had chosen not to vaccinate their nursery-school aged children. And it tracked the number of parents who had filed personal belief exemptions (PBEs), applications for permission to avoid vaccinations over a 5-year period to 2015. A disproportionate number of parents filing such forms were from Republican or conservative neighbourhoods, according to researcher Kevin A Estep, from the health administration and policy program at the university. Continue reading -> Brazil’s Federal Court Reviews Medicines Mailbox Patents 04/05/2018 Guest contributor This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Special Feature: Blocking Taiwan From Joining WHO Affects Global Health Security, Officials Say 09/04/2018 Catherine Saez TAIPEI, Taiwan - Two years after the victory of Taiwan Democratic Progressive Party (DPP) and President Tsai Ing-wen, Taiwan is feeling the effects of the DPP's position against the "One China principle." At the World Health Organization, China is allegedly successfully blocking Taiwan from participating in the annual World Health Assembly, and in a number of WHO technical meetings, officials say. Beyond the political dimension of the dissent between China and Taiwan, the situation may hurt the Taiwanese and global health security, Taiwanese officials said. Continue reading -> Global Health Governance Changing With Shift In Economic Centre Of Gravity, Speakers Say 16/03/2018 Catherine Saez Political and economic shifts have modified the post-war world order, and global health governance has to adapt to this new environment, speakers said at an academic event in Geneva this week. Among the changes: with the decline of United States funding for global health, new actors such as China and India could take leadership roles, they said. Continue reading -> UN Member States Briefed On Innovation And Access To Health Technologies 14/03/2018 William New NEW YORK -- A major event on innovation and access to health technologies took place at the United Nations in New York last week, in which UN member states were briefed on ideas and efforts to promote these issues at the forefront of global health policy. Continue reading -> New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Brazil’s Federal Court Reviews Medicines Mailbox Patents 04/05/2018 Guest contributor This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion Pharmaceuticals Inc. Eculizumab is used in the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disease. The product was approved by the US FDA for this indication in 2016. Brazil’s health care system spent $184.2 million to treat 442 patients with Soliris, an average of over $416,000 per patient. The patent office expects that more revocations may follow. This blog explains why this is. Continue reading -> Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Special Feature: Blocking Taiwan From Joining WHO Affects Global Health Security, Officials Say 09/04/2018 Catherine Saez TAIPEI, Taiwan - Two years after the victory of Taiwan Democratic Progressive Party (DPP) and President Tsai Ing-wen, Taiwan is feeling the effects of the DPP's position against the "One China principle." At the World Health Organization, China is allegedly successfully blocking Taiwan from participating in the annual World Health Assembly, and in a number of WHO technical meetings, officials say. Beyond the political dimension of the dissent between China and Taiwan, the situation may hurt the Taiwanese and global health security, Taiwanese officials said. Continue reading -> Global Health Governance Changing With Shift In Economic Centre Of Gravity, Speakers Say 16/03/2018 Catherine Saez Political and economic shifts have modified the post-war world order, and global health governance has to adapt to this new environment, speakers said at an academic event in Geneva this week. Among the changes: with the decline of United States funding for global health, new actors such as China and India could take leadership roles, they said. Continue reading -> UN Member States Briefed On Innovation And Access To Health Technologies 14/03/2018 William New NEW YORK -- A major event on innovation and access to health technologies took place at the United Nations in New York last week, in which UN member states were briefed on ideas and efforts to promote these issues at the forefront of global health policy. Continue reading -> New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Patents Without Examination: A Bad Solution For The 21st Century 30/04/2018 Guest contributor The Brazilian government's plan to deal with its patent backlog by making approvals without review is a recipe for disaster. It will move the backlog to the courts, with endless suits over duplicative and frivolous patents, write Arjun Jayadev and Dean Baker. Continue reading -> Special Feature: Blocking Taiwan From Joining WHO Affects Global Health Security, Officials Say 09/04/2018 Catherine Saez TAIPEI, Taiwan - Two years after the victory of Taiwan Democratic Progressive Party (DPP) and President Tsai Ing-wen, Taiwan is feeling the effects of the DPP's position against the "One China principle." At the World Health Organization, China is allegedly successfully blocking Taiwan from participating in the annual World Health Assembly, and in a number of WHO technical meetings, officials say. Beyond the political dimension of the dissent between China and Taiwan, the situation may hurt the Taiwanese and global health security, Taiwanese officials said. Continue reading -> Global Health Governance Changing With Shift In Economic Centre Of Gravity, Speakers Say 16/03/2018 Catherine Saez Political and economic shifts have modified the post-war world order, and global health governance has to adapt to this new environment, speakers said at an academic event in Geneva this week. Among the changes: with the decline of United States funding for global health, new actors such as China and India could take leadership roles, they said. Continue reading -> UN Member States Briefed On Innovation And Access To Health Technologies 14/03/2018 William New NEW YORK -- A major event on innovation and access to health technologies took place at the United Nations in New York last week, in which UN member states were briefed on ideas and efforts to promote these issues at the forefront of global health policy. Continue reading -> New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Special Feature: Blocking Taiwan From Joining WHO Affects Global Health Security, Officials Say 09/04/2018 Catherine Saez TAIPEI, Taiwan - Two years after the victory of Taiwan Democratic Progressive Party (DPP) and President Tsai Ing-wen, Taiwan is feeling the effects of the DPP's position against the "One China principle." At the World Health Organization, China is allegedly successfully blocking Taiwan from participating in the annual World Health Assembly, and in a number of WHO technical meetings, officials say. Beyond the political dimension of the dissent between China and Taiwan, the situation may hurt the Taiwanese and global health security, Taiwanese officials said. Continue reading -> Global Health Governance Changing With Shift In Economic Centre Of Gravity, Speakers Say 16/03/2018 Catherine Saez Political and economic shifts have modified the post-war world order, and global health governance has to adapt to this new environment, speakers said at an academic event in Geneva this week. Among the changes: with the decline of United States funding for global health, new actors such as China and India could take leadership roles, they said. Continue reading -> UN Member States Briefed On Innovation And Access To Health Technologies 14/03/2018 William New NEW YORK -- A major event on innovation and access to health technologies took place at the United Nations in New York last week, in which UN member states were briefed on ideas and efforts to promote these issues at the forefront of global health policy. Continue reading -> New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Global Health Governance Changing With Shift In Economic Centre Of Gravity, Speakers Say 16/03/2018 Catherine Saez Political and economic shifts have modified the post-war world order, and global health governance has to adapt to this new environment, speakers said at an academic event in Geneva this week. Among the changes: with the decline of United States funding for global health, new actors such as China and India could take leadership roles, they said. Continue reading -> UN Member States Briefed On Innovation And Access To Health Technologies 14/03/2018 William New NEW YORK -- A major event on innovation and access to health technologies took place at the United Nations in New York last week, in which UN member states were briefed on ideas and efforts to promote these issues at the forefront of global health policy. Continue reading -> New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
UN Member States Briefed On Innovation And Access To Health Technologies 14/03/2018 William New NEW YORK -- A major event on innovation and access to health technologies took place at the United Nations in New York last week, in which UN member states were briefed on ideas and efforts to promote these issues at the forefront of global health policy. Continue reading -> New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
New IP-Sharing Framework To Accelerate R&D 12/03/2018 Guest contributor Pharmaceutical R&D constantly leads to the generation of new intellectual property (IP), from clinical trial data to libraries of promising compounds. Not all IP assets generated by a company are used in their future R&D. When this happens, companies can choose instead to share them with other third-party researchers, under licensing agreements. The Access to Medicine Foundation has worked with BIO Ventures for Global Health (BVGH) to develop a framework for identifying which IP assets are most difficult for companies to share, yet most likely to speed up R&D of the medicines and vaccines needed by people living in low- and middle-income countries (LMICs), write Clarke B. Cole and Katie Graef. Continue reading -> A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
A Look At The Role Of Governments, Universities, Science In Health Innovation & Access 05/03/2018 Catherine Saez Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents. Continue reading -> Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium 02/03/2018 Catherine Saez The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies. Continue reading -> Posts navigation Older postsNewer posts